Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Harrow Health, Inc.NASDAQ: HROW
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $5.9M rose 94.8% year over year, ahead of the +17.2% change in trailing-twelve-month research & development. Sequentially, it rose 80.1% from the prior quarter. Over 3 fiscal years it compounded at +61.5% a year.
Context
- Research & development amounted to 4.7% of revenue in FY2025, down 1.4 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +94.8% holds above the trailing-twelve-month pace of +17.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 12.85M USD
- Year-over-year change
- +5.0%
- 4-year CAGR
- +3.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.85M | +5.0% |
| FY2024 | 2024-12-31 | 12.23M | +83.9% |
| FY2023 | 2023-12-31 | 6.65M | +118.1% |
| FY2022 | 2022-12-31 | 3.05M | -72.5% |
| FY2021 | 2021-12-31 | 11.08M | — |
Research & Development vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.2% is the 5th highest of 8, against a peer median of +23.6%.
- Research & development amounts to 5.7% of revenue for HROW, versus a peer median of 1752.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $404M USD | +12.5% | +6.5% | 7.6% | |
| LTM Mar 2026 | $234.61M USD | +45.4% | +64.5% | 3080.9% | |
| LTM Mar 2026 | $220.45M USD | +47.2% | +54.5% | 423.6% | |
| LTM Sep 2026 | $208.43M USD | +23.6% | -12.0% | — | |
| LTM Sep 2026 | $115.59M USD | +83.0% | +14.7% | 16.9% | |
| LTM Mar 2026 | CHF 56.48M CHF | +0.9% | +34.9% | 11206.4% | |
| LTM Mar 2026 | $21.25M USD | -43.8% | +8527.1% | 6378.2% | |
| LTM Mar 2026 | $15.36M USD | +17.2% | +61.5% | 5.7% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $365.75K USD | — | — | — |
| Peer median (excluding HROW) | — | +23.6% | +34.9% | 1752.3% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.48M | 88.6M | 130.19M | 199.61M | 272.3M |
| Cost of Revenue | 18.21M | 25.38M | 39.64M | 49.25M | 67.93M |
| Gross Profit | 54.26M | 63.21M | 90.55M | 150.37M | 204.37M |
| Gross Margin | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| Research & Development | 11.08M | 3.05M | 6.65M | 12.23M | 12.85M |
| Selling, General & Admin | 39.82M | 0 | 0 | 0 | 152.91M |
| Operating Expenses | 52.65M | 61.29M | 90.12M | 141.55M | 165.76M |
| Depreciation & Amortization | 1.74M | 2.83M | 11.14M | 13.05M | 18.91M |
| EBITDA | 5.1M | (3.94M) | 11.95M | 22.13M | 41.36M |
| EBITDA Margin | 7.0% | -4.4% | 9.2% | 11.1% | 15.2% |
| Operating Income | 1.61M | 1.92M | 431K | 8.82M | 38.61M |
| Operating Margin | 2.2% | 2.2% | 0.3% | 4.4% | 14.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.44M | 7.24M | 21.32M | 22.79M | 24.18M |
| Other Income / Expenses | (19.49M) | (15.93M) | (24.14M) | (26.14M) | (40.33M) |
| Income Before Tax | (17.87M) | (14.01M) | (23.71M) | (17.32M) | (1.72M) |
| Pre-Tax Margin | -24.7% | -15.8% | -18.2% | -8.7% | -0.6% |
| Income Tax Expense | 133K | 75K | 701K | 161K | 3.42M |
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Net Margin | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% |
| EPS (Basic) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| EPS (Diluted) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| Weighted Avg Shares | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
| Weighted Avg Shares (Diluted) | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.